EpiVax, Inc. - Product Pipeline Review - 2016

  • ID: 3802736
  • Company Profile
  • 36 pages
  • Global Markets Direct
1 of 3
EpiVax, Inc. - Product Pipeline Review - 2016

Summary

‘EpiVax, Inc. - Product Pipeline Review - 2016’, provides an overview of the EpiVax, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by EpiVax, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of EpiVax, Inc.
- The report provides overview of EpiVax, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses EpiVax, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features EpiVax, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate EpiVax, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for EpiVax, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding EpiVax, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables

List of Figures

EpiVax, Inc. Snapshot

EpiVax, Inc. Overview

Key Information

Key Facts

EpiVax, Inc. - Research and Development Overview

Key Therapeutic Areas

EpiVax, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

EpiVax, Inc. - Pipeline Products Glance

EpiVax, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

EpiVax, Inc. - Drug Profiles

Deimmunized FVIII

Product Description

Mechanism of Action

R&D Progress

Epi-13

Product Description

Mechanism of Action

R&D Progress

Helicobacter pylori vaccine

Product Description

Mechanism of Action

R&D Progress

influenza [strain H1N1] vaccine

Product Description

Mechanism of Action

R&D Progress

onabotulinumtoxin A

Product Description

Mechanism of Action

R&D Progress

smallpox vaccine

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptides for Allergy

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptides for Pompe disease

Product Description

Mechanism of Action

R&D Progress

tuberculosis vaccine

Product Description

Mechanism of Action

R&D Progress

tularaemia vaccine

Product Description

Mechanism of Action

R&D Progress

equine encephalitis vaccine

Product Description

Mechanism of Action

R&D Progress

HIV vaccine

Product Description

Mechanism of Action

R&D Progress

influenza [strain A/H7N9] vaccine

Product Description

Mechanism of Action

R&D Progress

EpiVax, Inc. - Pipeline Analysis

EpiVax, Inc. - Pipeline Products by Target

EpiVax, Inc. - Pipeline Products by Route of Administration

EpiVax, Inc. - Pipeline Products by Molecule Type

EpiVax, Inc. - Pipeline Products by Mechanism of Action

EpiVax, Inc. - Recent Pipeline Updates

EpiVax, Inc. - Dormant Projects

EpiVax, Inc. - Company Statement

EpiVax, Inc. - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 36List of Tables

EpiVax, Inc., Key Information

EpiVax, Inc., Key Facts

EpiVax, Inc. - Pipeline by Indication, 2016

EpiVax, Inc. - Pipeline by Stage of Development, 2016

EpiVax, Inc. - Monotherapy Products in Pipeline, 2016

EpiVax, Inc. - Preclinical, 2016

EpiVax, Inc. - Discovery, 2016

EpiVax, Inc. - Pipeline by Target, 2016

EpiVax, Inc. - Pipeline by Route of Administration, 2016

EpiVax, Inc. - Pipeline by Molecule Type, 2016

EpiVax, Inc. - Pipeline Products by Mechanism of Action, 2016

EpiVax, Inc. - Recent Pipeline Updates, 2016

EpiVax, Inc. - Dormant Developmental Projects,2016 32List of Figures

EpiVax, Inc. - Pipeline by Top 10 Indication, 2016

EpiVax, Inc. - Pipeline by Stage of Development, 2016

EpiVax, Inc. - Monotherapy Products in Pipeline, 2016

EpiVax, Inc. - Pipeline by Target, 2016

EpiVax, Inc. - Pipeline by Molecule Type, 2016

EpiVax, Inc. - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll